Good News for TNBC MBC Patients Whoa are PD-L1+!

Greetings,

Great news! TNBC MBC patients whose tumors express PD-L1 (PD-L1 stained tumor-infiltrating immune cells of any intensity covering ≥ 1% of the tumor area) may be eligible to receive Atezolizumab (Tecentriq) with Abraxane.

Atezolizumab is an immunotherapy drug that works well in combination with chemotherapy. Atezolizumab was closely studied in the IMPassion130 trial, which determined that TNBC MBC patients whose tumors expressed PD-L1 had a median Overall Survival of at least 25 months on Atezolizumab with Abraxane, vs. 15.5 months on Abraxane alone. As a result, in March 2019 the FDA granted accelerated approval to Atezolizumab in combination with Abraxane for TNBC patients with unresectable locally advanced or metastatic disease whose tumors express PD-L1. The FDA has also approved the VENTANA PD-L1 (SP142) Assay as a companion diagnostic device for selecting TNBC patients for this therapy. From: https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm633065.htm

This newly-released information has been incorporated into my book, "The Insider's Guide to Metastatic Breast Cancer" which is available in paperback and eBook formats on Amazon at https://www.amazon.com/Insiders-Guide-Metastatic-Breast-Cancer/dp/179586060X/ref=tmm_pap_swatch_0?_encoding=UTF8&qid=&sr=

A complimentary .pdf is available by emailing me at bestbird@hotmail.com

Best wishes!